Resources Repository
-
ArticlePublication 2016Measuring Benefits of Opioid Misuse Treatment: HRQOL of Opioid-Dependent Individuals and Spouses
This study sought to understand how the general public views the quality of life effects …
This study sought to understand how the general public views the quality of life effects of opioid misuse and opioid use disorder on an individual and his/her spouse, measured in terms used in economic evaluations. The study design was a cross-sectional internet survey of a US population-representative respondent panel conducted December 2013-January 2014, with a total of 2054 randomly selected adults, of whom 51.1% were male. The mean individual utility ranged from 0.574 for active injection…
Health Outcomes | Economics/Finance | Chronic Disease/Risk | Preferences/Values | Mental Health | Health/Medicine | North America -
ArticlePublication 2016Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to …
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to the health service provider. Effective approaches to increase the implementation of guidance are needed. Since investment in activities that improve implementation competes for funding against other health generating interventions, it should be assessed in term of its costs and benefits. In 2010, the National Institute for Health and Care Excellence released a clinical guideline recommending natriuretic peptide (NP) testing in…
Health Outcomes | Economics/Finance | Chronic Disease/Risk | Cost-Effectiveness Analysis | Operations Research | Health Systems | Clinical Care | Health/Medicine | Europe -
ArticlePublication 2015Population Health Model (POHEM): An Overview
This paper provides an overview of the rationale, methodology and applications of the Population Health …
This paper provides an overview of the rationale, methodology and applications of the Population Health Model (POHEM). POHEM is a health microsimulation model, developed at Statistics Canada in the early 1990s. The authors describe that POHEM draws together rich multivariate data from a wide range of sources to simulate the lifecycle of the Canadian population, specifically focusing on aspects of health. The model dynamically simulates individuals’ disease states, risk factors, and health determinants, in order…
Calibration/Validation | Economics/Finance | Chronic Disease/Risk | Costing Methods | Evidence Synthesis | Mathematical Models | Microsimulation | Health Systems | Policy/Regulation | Clinical Care | Health/Medicine | North America -
ArticlePublication 2014Economic Implications of Population Ageing in China & India: Introduction to the Special Issue
In this special issue of The Journal of the Economics of Ageing, we focus on economic …
In this special issue of The Journal of the Economics of Ageing, we focus on economic aspects of population ageing in the world’s two population superpowers: China and India. China and India have been the subject of comparison for many years. Observations about their relative political and economic development abound (see for example Sen, 2013), but little analysis is currently available of their comparative demographic trajectories and the possible economic consequences of the population ageing that they are both undergoing. These demographic…
Health Outcomes | Economics/Finance | Chronic Disease/Risk | Costing Methods | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Asia & Pacific -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Calibration/Validation | Economics/Finance | Chronic Disease/Risk | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Clinical Care | Health/Medicine | Science/Technology | Sub-Saharan Africa -
ArticlePublication 2009Cost Effectiveness Analysis of Including Boys in a HPV Vaccination Program in the U.S.
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a …
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a routine human papillomavirus (HPV) vaccination program for preadolescent girls. The analysis included girls and boys aged 12 years; interventions included HPV vaccination of girls alone and of girls and boys in the context of screening for cervical cancer. The authors found that with 75% vaccination coverage and an assumption of complete, lifelong vaccine efficacy, routine HPV vaccination of 12-year-old girls…
Calibration/Validation | Economics/Finance | Chronic Disease/Risk | Dynamic Transmission | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Clinical Care | Health/Medicine | North America -
ArticlePublication 2008Health and Economic Implications of HPV Vaccination in the U.S.
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical …
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical carcinogenesis to compare the health and economic outcomes of vaccinating preadolescent girls in the US (at 12 years of age), and vaccinating older girls and women in catch-up programs (to 18, 21, or 26 years of age). The study also examined the health benefits of averting other HPV-16-related and HPV-18-related cancers, the prevention of HPV-6-related and HPV-11-related genital warts and…
Calibration/Validation | Economics/Finance | Chronic Disease/Risk | Dynamic Transmission | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Clinical Care | Health/Medicine | Science/Technology | North America -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, …
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for vaccination of young adolescent girls against human papillomavirus (HPV) types 16 and 18. The authors used population-based and epidemiologic data for 25 countries in Asia (22 GAVI-Alliance eligible countries, Thailand, China and Japan). They found that an absolute reduction in lifetime cancer risk varied across countries, depending on incidence,…
Calibration/Validation | Economics/Finance | Chronic Disease/Risk | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Science/Technology | Asia & Pacific -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in Latin America and the Caribbean
This article reports on a model-based approach estimated averted cervical cancer cases and deaths, disability-adjusted …
This article reports on a model-based approach estimated averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for human papillomavirus (HPV) vaccination of young adolescent girls using population and epidemiologic data for 33 countries in Latin America and the Caribbean (LAC). The authors found that an absolute reduction in lifetime cancer risk varied between countries, depending on incidence, proportion attributable to HPV-16 and 18, and population age-structure; for…
Calibration/Validation | Economics/Finance | Chronic Disease/Risk | Costing Methods | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | Science/Technology | Latin America & Caribbean